Eli Lilly sues over knockoffs of signature weight loss drug, Zepbound
Eli Lilly sued three medical spas and online vendors for selling products that claim to contain the ingredient in its weight-loss medicine Zepbound.
Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug
Eli Lilly sues vendors for selling unauthorized tirzepatide amid resolved shortages. Lawsuits target vendors offering counterfeit versions of Zepbound and Mounjaro
Mangoceuticals To Defend Against Eli Lilly's Lawsuit Over Alleged Copying Of Weight-Loss Drugs
Mangoceuticals Inc. (MGRX) announced that Eli Lilly has made public allegations and filed a lawsuit against the company, claiming
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its shortage list.
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
Lilly sues online vendors, medical spa over copycat weight-loss drugs
Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.
Mangoceuticals refutes claims made by Lilly in weight-loss drug lawsuit
Mangoceuticals (MGRX) said it strongly refutes claims made in a lawsuit filed by Eli Lilly (LLY) over a compounded version of Lilly’s weight-loss drug tirzepatide. Read more here.
1 Reason to Buy Eli Lilly Stock Hand Over Fist Right Now
Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...
FiercePharma20d
Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have ...
Seeking Alpha7d
Eli Lilly’s Zepbound to undergo first-of-its-kind study on economic impact
Eli Lilly (NYSE:LLY ... study to evaluate the economic effects of the company’s popular weight loss therapy, tirzepatide, branded as Zepbound. Writing for the U.K.’s The Telegraph newspaper ...
This is Huge News For Eli Lilly Investors
As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
MangoRx remains committed to its mission and plans to continue to enhance patient care by offering new and innovative solutions while striving to comply with federal, state and local regulatory ...
Seeking Alpha21d
Lilly looking to test Zepbound as health maintenance drug: report
Eli Lilly (NYSE:LLY) is reportedly looking ... Ricks added that the company still regards using Zepbound for cosmetic weight loss as “inappropriate.” Zepbound, also known as tirzepatide ...
Benzinga.com27d
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Eli Lilly is building a case against businesses that are selling knockoffs of the company's Zepbound and Monjaro. Compounding pharmacies have been capitalizing on Lilly seeing supply ...
Eli Lilly and Company (NYSE:LLY) Shares Purchased by Whittier Trust Co. of Nevada Inc.
Whittier Trust Co. of Nevada Inc. boosted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 7.4% during the ...